In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AAM Slams USMCA Over Mexico Biologics Impact

Doubling Data Exclusivity Will Only Harm Patients, Not Boost Industry

Executive Summary

Biologic exclusivity provisions in the proposed USMCA US-Mexico-Canada trade agreement will not create a new market for original biologics in Mexico, as firms have been selling them in the country since before 2001, the US Association for Accessible Medicines has argued in response to brand industry claims.

You may also be interested in...



AAM Welcomes Potential USMCA Revision

The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.

Congress Puts Pressure On USTR Over Deal With Canada And Mexico

More than 100 members of the US Congress have written to US Trade Representative ambassador Robert Lighthizer urging changes to the US-Mexico-Canada Agreement trade deal that is due to replace the previous NAFTA agreement, with biologic competition and access highlighted as key concerns.

AAM slams USMCA trade deal

Failure to change provisions of the recently agreed US-Mexico- Canada Free Trade Agreement (USMCA) will “exacerbate the lagging biosimilar market in the US”, slow biosimilar and generic development, and create inconsistencies with US law, according to the US Association for Accessible Medicines (AAM).

Related Content

Topics

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel